Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, is investigating whether NextCure, Inc. (“NextCure” or the “Company”) (NASDAQ: NXTC) or certain of its officers and directors violated federal securities laws.  If you purchased NextCure securities pursuant and/or traceable to NextCure’s offering in November 2019 or have otherwise suffered a loss, realized or unrealized, you are encouraged to contact Scott+Scott attorney Jonathan Zimmerman at (888) 398-9312 for more information.


NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases.

On November 18, 2019, NextCure conducted a public offering, making available over 4 million shares of common stock to the investing public at $36.75 per share.

On July 13, 2020, NextCure announced it was discontinuing the non-small cell lung cancer (NSCLC) and ovarian cancer cohorts of its NC318 monotherapy phase 1/2 trial, as well as the departure of its Chief Medical Officer.

On this news, NextCure’s stock declined over 54%, falling from $17.88 per share on July 10, 2020 to close on July 13, 2020 at $8.15 per share.

What You Can Do

If you purchased NextCure securities, and you wish to discuss this investigation, please contact attorney Jonathan Zimmerman at (888) 398-9312, or at

About Scott+Scott Attorneys at Law LLP

Scott+Scott has significant experience in prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States.  The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Connecticut, California, and Ohio.

Attorney Advertising


Jonathan Zimmerman

Scott+Scott Attorneys at Law LLP

230 Park Ave, 17th Floor, NY, NY 10169

(888) 398-9312


  • Action: NextCure, Inc.
  • Number of Shares:Buy Date:Price Per Share: 
  • Number of Shares:Sell Date:Price Per Share: